

## Special Issue

# Advances in the Synthesis and Molecular Design of Bioactive Heterocycles as Anticancer and Antioxidant Agents

### Message from the Guest Editor

Molecular symmetry and asymmetry play crucial roles in the development of bioactive compounds, particularly in anticancer and antioxidant agents. Symmetric molecules often display predictable properties, facilitating their design and synthesis, making them effective candidates for targeted therapies. These compounds can uniformly interact with biological targets, allowing for efficient drug delivery and pharmacological action. On the other hand, asymmetric molecules, with their structural complexity, offer versatility in binding interactions to biological targets. Their irregular structure often allows higher adaptability to a broader range of targets, which can be advantageous for overcoming drug resistance and improving therapeutic outcomes. Both symmetric and asymmetric designs are being explored in combination therapies to increase the synergy of anticancer and antioxidant effects, contributing to the development of more effective and targeted treatments. This exploration opens new frontiers in molecular design for next-generation cancer and antioxidant agents, with improved pharmacokinetics, bioavailability, and potency.

---

### Guest Editor

Dr. Anca Stana

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Iuliu Hațieganu University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania

---

### Deadline for manuscript submissions

20 August 2026



## Current Issues in Molecular Biology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/si/231448](https://mdpi.com/si/231448)

*Current Issues in Molecular Biology*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cimb@mdpi.com](mailto:cimb@mdpi.com)

[mdpi.com/journal/  
cimb](https://mdpi.com/journal/cimb)





# Current Issues in Molecular Biology

an Open Access Journal  
by MDPI

Impact Factor 3.0  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/journal/  
cimb](https://mdpi.com/journal/cimb)



## About the Journal

### Message from the Editor-in-Chief

---

#### Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Molecular Medicine, University of Otago,  
Christchurch 8140, New Zealand

---

#### Author Benefits

##### High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

##### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

##### Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.